Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. FDA proposes to ease sexual abstinence rule for blood donors

Published 01/27/2023, 12:14 PM
Updated 01/27/2023, 03:50 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

(Reuters) - The U.S. health regulator on Friday proposed new blood donation guidelines for men who have sex with men that are based on individual risk rather than across-the-board requirements, a move it said is in line with other countries and will help ensure the U.S. blood supply.

The U.S. Food and Drug Administration said the rules aim to reduce the risk of transfusion-transmitted HIV and are similar to those in the UK and Canada.

The proposed rule comes several years after the FDA reversed a 1980s guideline, which banned men who have sex with men from donating blood, but said they had to abstain from sex for at least a year before donating.

In 2020, the agency shortened the abstinence period to three months amid a pandemic-driven shortage of blood supply.

The removal of time-based deferrals also applies to women who have sex with the men who have sex with other men, the FDA said.

Under the new proposal, any prospective donor - regardless of gender or sexual orientation - other than those who report having a new sexual partner or multiple partners and having anal sex in the past three months, will be eligible to donate blood, provided all other eligibility criteria are met.

The regulator has also proposed new time limits for people taking pre-exposure prophylaxis or post-exposure prophylaxis treatments used for HIV prevention to reflect data showing that these medications may delay the detection of HIV and result in false negatives.

People taking oral medication would be deferred for three months after the most recent dose and those receiving injections by two years from the last dose.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The FDA will review public comments before finalizing the proposal.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.